Merck & Co. Statistics
Total Valuation
Merck & Co. has a market cap or net worth of $265.03 billion. The enterprise value is $288.19 billion.
| Market Cap | 265.03B |
| Enterprise Value | 288.19B |
Important Dates
The next estimated earnings date is Tuesday, February 3, 2026, before market open.
| Earnings Date | Feb 3, 2026 |
| Ex-Dividend Date | Dec 15, 2025 |
Share Statistics
Merck & Co. has 2.48 billion shares outstanding. The number of shares has decreased by -0.91% in one year.
| Current Share Class | 2.48B |
| Shares Outstanding | 2.48B |
| Shares Change (YoY) | -0.91% |
| Shares Change (QoQ) | -0.60% |
| Owned by Insiders (%) | 0.05% |
| Owned by Institutions (%) | 79.35% |
| Float | 2.48B |
Valuation Ratios
The trailing PE ratio is 14.13 and the forward PE ratio is 12.36. Merck & Co.'s PEG ratio is 1.28.
| PE Ratio | 14.13 |
| Forward PE | 12.36 |
| PS Ratio | 4.18 |
| Forward PS | 3.94 |
| PB Ratio | 5.12 |
| P/TBV Ratio | 17.73 |
| P/FCF Ratio | 20.31 |
| P/OCF Ratio | 15.53 |
| PEG Ratio | 1.28 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 9.14, with an EV/FCF ratio of 22.09.
| EV / Earnings | 15.14 |
| EV / Sales | 4.49 |
| EV / EBITDA | 9.14 |
| EV / EBIT | 10.60 |
| EV / FCF | 22.09 |
Financial Position
The company has a current ratio of 1.66, with a Debt / Equity ratio of 0.80.
| Current Ratio | 1.66 |
| Quick Ratio | 1.09 |
| Debt / Equity | 0.80 |
| Debt / EBITDA | 1.30 |
| Debt / FCF | 3.17 |
| Interest Coverage | 21.34 |
Financial Efficiency
Return on equity (ROE) is 39.49% and return on invested capital (ROIC) is 19.31%.
| Return on Equity (ROE) | 39.49% |
| Return on Assets (ROA) | 13.76% |
| Return on Invested Capital (ROIC) | 19.31% |
| Return on Capital Employed (ROCE) | 26.94% |
| Revenue Per Employee | $856,467 |
| Profits Per Employee | $253,787 |
| Employee Count | 75,000 |
| Asset Turnover | 0.52 |
| Inventory Turnover | 2.24 |
Taxes
In the past 12 months, Merck & Co. has paid $2.77 billion in taxes.
| Income Tax | 2.77B |
| Effective Tax Rate | 12.71% |
Stock Price Statistics
The stock price has increased by +7.37% in the last 52 weeks. The beta is 0.30, so Merck & Co.'s price volatility has been lower than the market average.
| Beta (5Y) | 0.30 |
| 52-Week Price Change | +7.37% |
| 50-Day Moving Average | 94.60 |
| 200-Day Moving Average | 85.43 |
| Relative Strength Index (RSI) | 70.87 |
| Average Volume (20 Days) | 14,501,176 |
Short Selling Information
The latest short interest is 37.16 million, so 1.50% of the outstanding shares have been sold short.
| Short Interest | 37.16M |
| Short Previous Month | 27.63M |
| Short % of Shares Out | 1.50% |
| Short % of Float | 1.50% |
| Short Ratio (days to cover) | 2.34 |
Income Statement
In the last 12 months, Merck & Co. had revenue of $64.24 billion and earned $19.03 billion in profits. Earnings per share was $7.56.
| Revenue | 64.24B |
| Gross Profit | 50.01B |
| Operating Income | 27.19B |
| Pretax Income | 21.82B |
| Net Income | 19.03B |
| EBITDA | 31.52B |
| EBIT | 27.19B |
| Earnings Per Share (EPS) | $7.56 |
Balance Sheet
The company has $18.21 billion in cash and $41.37 billion in debt, giving a net cash position of -$23.16 billion or -$9.33 per share.
| Cash & Cash Equivalents | 18.21B |
| Total Debt | 41.37B |
| Net Cash | -23.16B |
| Net Cash Per Share | -$9.33 |
| Equity (Book Value) | 51.91B |
| Book Value Per Share | 20.85 |
| Working Capital | 18.93B |
Cash Flow
In the last 12 months, operating cash flow was $17.07 billion and capital expenditures -$4.02 billion, giving a free cash flow of $13.05 billion.
| Operating Cash Flow | 17.07B |
| Capital Expenditures | -4.02B |
| Free Cash Flow | 13.05B |
| FCF Per Share | $5.26 |
Margins
Gross margin is 77.85%, with operating and profit margins of 42.33% and 29.63%.
| Gross Margin | 77.85% |
| Operating Margin | 42.33% |
| Pretax Margin | 33.96% |
| Profit Margin | 29.63% |
| EBITDA Margin | 49.07% |
| EBIT Margin | 42.33% |
| FCF Margin | 20.31% |
Dividends & Yields
This stock pays an annual dividend of $3.40, which amounts to a dividend yield of 3.18%.
| Dividend Per Share | $3.40 |
| Dividend Yield | 3.18% |
| Dividend Growth (YoY) | 5.13% |
| Years of Dividend Growth | 14 |
| Payout Ratio | 43.41% |
| Buyback Yield | 0.91% |
| Shareholder Yield | 4.10% |
| Earnings Yield | 7.18% |
| FCF Yield | 4.92% |
Analyst Forecast
The average price target for Merck & Co. is $111.93, which is 4.82% higher than the current price. The consensus rating is "Buy".
| Price Target | $111.93 |
| Price Target Difference | 4.82% |
| Analyst Consensus | Buy |
| Analyst Count | 15 |
| Revenue Growth Forecast (5Y) | 1.79% |
| EPS Growth Forecast (5Y) | 6.20% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on February 17, 1999. It was a forward split with a ratio of 2:1.
| Last Split Date | Feb 17, 1999 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Merck & Co. has an Altman Z-Score of 3.89 and a Piotroski F-Score of 5.
| Altman Z-Score | 3.89 |
| Piotroski F-Score | 5 |